冠状动脉旁路移植术后静脉移植物处理液的多层CT序贯评估
在孤立性冠状动脉旁路移植术患者中,将两根大隐静脉移植物随机分配至DuraGraft或肝素化生理盐水处理,采用多层CT血管造影在1、3、12个月评估管壁厚度、管腔直径和最大狭窄。3个月时两组无显著差异,12个月时DuraGraft组整体及近端段平均管壁厚度较小,近端段管壁厚度变化和最大狭窄增加也较小,但需更大样本长期随访评估临床结局。
要点
- DuraGraft处理静脉移植物在12个月时管壁厚度小于生理盐水组
- 近端5cm段获益更明显,管壁增厚和最大狭窄增加均较小
- 3个月时两组管壁厚度、管腔直径和最大狭窄无显著差异
核心结论
- DuraGraft在12个月时对静脉移植物管壁厚度显示出有利影响,尤其在近端段。
研究设计与样本
- 在孤立性冠状动脉旁路移植术患者中,将2根大隐静脉移植物随机分配至DuraGraft或肝素化生理盐水处理。
- 采用多层CT血管造影在1、3、12个月评估管壁厚度(主要终点为3个月)、管腔直径和最大狭窄。
主要发现
- 3个月时DuraGraft组与生理盐水组(各125根)在管壁厚度、管腔直径和最大狭窄方面无显著变化。
- 12个月时DuraGraft组整体平均管壁厚度较小(0.12 ± 0.06 vs 0.20 ± 0.31 mm;P = .02),近端段也较小(0.11 ± 0.03 vs 0.21 ± 0.33 mm;P = .01)。
- 生理盐水组近端段管壁厚度变化更大(0.09 ± 0.29 vs 0.00 ± 0.03 mm;P = .04),最大狭窄增加更大(4.7% ± 12.7% vs 0.2% ± 3.8%;P = .01)。
- DuraGraft组9根和生理盐水组11根移植物发生闭塞或血栓形成;1例心肌梗死与生理盐水移植物闭塞相关;无死亡或再次血运重建。
关键数值与推荐
- 主要终点为3个月时管壁厚度变化,两组间无显著差异。
- 12个月时DuraGraft组整体管壁厚度0.12 ± 0.06 mm vs 生理盐水组0.20 ± 0.31 mm(P = .02)。
- 12个月时近端段管壁厚度DuraGraft组0.11 ± 0.03 mm vs 生理盐水组0.21 ± 0.33 mm(P = .01)。
- 近端段管壁厚度变化DuraGraft组0.00 ± 0.03 mm vs 生理盐水组0.09 ± 0.29 mm(P = .04)。
- 近端段最大狭窄增加DuraGraft组0.2% ± 3.8% vs 生理盐水组4.7% ± 12.7%(P = .01)。
临床怎么用
- 对于冠状动脉旁路移植术中使用大隐静脉桥的患者,术中采用DuraGraft处理可能有助于减轻12个月时静脉桥管壁增厚和近端狭窄进展。
- 该获益主要在12个月时显现,3个月时未见显著差异,临床决策需结合长期结局证据。
局限性
- 需要更大样本的长期随访研究来评估DuraGraft对临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effect of DuraGraft (Somahlution Inc, Jupiter, Fla), an intraoperative graft treatment, on saphenous vein grafts in patients undergoing isolated coronary artery bypass grafting. METHODS: Within patients, 2 saphenous vein grafts were randomized to DuraGraft or heparinized saline. Multidetector computed tomography angiography at 1, 3, and 12 months assessed change in wall thickness (primary end point at 3 months), lumen diameter, and maximum narrowing for the whole graft and the proximal 5-cm segment. Safety end points included graft occlusion, death, myocardial infarction, and repeat revascularization. RESULTS: At 3 months, no significant changes were observed between DuraGraft- and saline-treated grafts (125 each) for wall thickness, lumen diameter, and maximum narrowing. At 12 months, DuraGraft-treated grafts demonstrated smaller mean wall thickness, overall (0.12 ± 0.06 vs 0.20 ± 0.31 mm; P = .02) and in the proximal segment (0.11 ± 0.03 vs 0.21 ± 0.33 mm; P = .01). Changes in wall thickness were greater in the proximal segment of saline-treated grafts (0.09 ± 0.29 vs 0.00 ± 0.03 mm; P = .04). Increase in maximum graft narrowing was larger in the proximal segment in the saline-treated grafts (4.7% ± 12.7% vs 0.2% ± 3.8%; P = .01). Nine DuraGraft and 11 saline grafts had occluded or thrombosed. One myocardial infarction was associated with a saline graft occlusion. No deaths or revascularizations were observed. CONCLUSIONS: DuraGraft demonstrated a favorable effect on wall thickness at 12 months, particularly in the proximal segment. Longer-term follow-up in larger studies is needed to evaluate the effect on clinical outcomes.
引用
- Perrault LP, Carrier M, Voisine P, et al. Sequential multidetector computed tomography assessments after venous graft treatment solution in coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2019. PMID: 31866081. doi:10.1016/j.jtcvs.2019.10.115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。